NeoStem: VSEL Technology Is Only the Beginning ...
M.E. Garza submits:
Earlier this week, I published a list of several stocks you want to own this week, and certainly on the list was one of the companies we've been following most closely, Neostem, Inc. (NBS). If you still haven't picked up any shares, you may want to, because things are about to get a lot more interesting for this undervalued "stem cell play with a twist."Recently, the company announced the recent approval from the State Food and Drug Administration (SFDA) in China to manufacture the sterile active pharmaceutical ingredient (API) of the anti-infective cloxacillin sodium. This is the second of seven drugs in Erye's pipeline to be approved since the October 31st, 2009, acquisition of the 51% interest in Erye. Both drugs are on the China’s National Medical Reimbursement Insurance list, and thus eligible for reimbursement by the government's healthcare programs. The Commercial launch for both drugs is planned for this summer.Complete Story »
- Original article
- Login or register to post comments
